Our Research

Safety of Allogeneic Mesenchymal Stromal Cell Therapy Across Human Clinical Indications: A Systematic Review of Landmark Clinical Trials and Published Safety

Summary: Our research reviews the safety of allogeneic mesenchymal stromal cell therapy across multiple human clinical indications, including cardiovascular, pulmonary, musculoskeletal, autoimmune, gastrointestinal, and renal conditions. Across landmark trials and major pooled analyses, the evidence supports a favorable safety profile, with no consistent signal of frequent treatment-related serious adverse events. The most commonly reported treatment-related effect has been transient fever, while no increased risk of infection, malignancy, or treatment-related mortality has been consistently identified. These findings support the continued clinical development of allogeneic MSC therapy as a scalable and generally well-tolerated regenerative medicine platform.

For patients interested in the clinical application of this research, learn more about our stem cell therapy program.

Mesenchymal Stromal Cells as Modulators of Chronic Inflammation, Inflammaging, and Age-Related Disease: A Systematic Review

Summary: This study is about chronic low-grade inflammation, often called inflammaging, which is a major driver of aging and many age-related diseases. In our systematic review of clinical and preclinical studies, mesenchymal stem cells (MSCs) consistently showed the ability to reduce key pro-inflammatory markers while supporting anti-inflammatory immune signaling. These findings suggest MSC therapy may help address chronic inflammation at a biological level and may have important potential in age-related and degenerative conditions.

For patients interested in the clinical application of this research, learn more about our stem cell therapy program.

Intravenous Mesenchymal Stromal Cells for Severe and Critical COVID-19: Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials

Summary: This study examined high-quality clinical trials evaluating intravenous mesenchymal stromal cell therapy in adults with severe and critical COVID-19. By reviewing randomized, placebo-controlled studies, the analysis assessed short-term outcomes related to inflammation and clinical severity. The findings identified consistent reductions in key inflammatory markers and suggested a favorable trend in short-term outcomes, supporting continued investigation of MSC-based immunomodulatory approaches in critical illness.

For patients interested in the clinical application of this research, learn more about our stem cell therapy program.

Allogeneic Umbilical Cord Mesenchymal Stromal Cells for Knee Osteoarthritis: Systematic Review and Meta-Analysis of Controlled Injection Trials

Summary: This study reviewed controlled clinical trials evaluating intra-articular umbilical cord–derived mesenchymal stromal cell (MSC) injections for knee osteoarthritis. The analysis focused on longer-term pain outcomes and compared MSC injections with commonly used standard therapies. Across included studies, results showed a consistent direction of benefit at 12 months, supporting further clinical evaluation of MSC-based injection therapies for osteoarthritis.

For patients interested in the clinical application of this research, learn more about our stem cell therapy program.

Intradiscal Mesenchymal Stromal/Stem Cell Therapy for Lumbar Discogenic Low Back Pain Due to Degenerative Disc Disease: A Systematic Review

Summary: This study examines degenerative disc disease, a major cause of chronic low back pain and disability worldwide. In our systematic review of human clinical studies, intradiscal mesenchymal stromal/stem cell (MSC) therapy was consistently associated with reductions in pain and improvements in functional disability, commonly measured using Visual Analog Scale (VAS) and Oswestry Disability Index (ODI) scores. Across the clinical literature reviewed, MSC therapy demonstrated encouraging clinical outcomes with generally favorable safety profiles reported during follow-up periods extending up to several years. These findings suggest that MSC therapy may represent a promising biologically based approach for patients with discogenic low back pain associated with degenerative disc disease.

For patients interested in the clinical application of this research, learn more about our stem cell therapy program.

Allogeneic Mesenchymal Stromal Cell-Based Therapies for Diabetic Foot Ulcers: Systematic Review and Meta-Analysis of Controlled Topical and Local Delivery Trials

Summary: This study reviewed controlled clinical trials evaluating allogeneic mesenchymal stromal cell-based therapies for diabetic foot ulcers, delivered topically and or by local injection as an adjunct to standard wound care. Across included studies, MSC based approaches showed higher closure rates and greater wound area reduction, with no clear signal of increased serious treatment related adverse events. Effects on amputation outcomes were less certain due to limited event reporting, supporting the need for larger randomized trials with standardized protocols and consistent outcome reporting.

For patients interested in the clinical application of this research, learn more about our stem cell therapy program.